Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott files Humira for Crohn’s

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Abbott has submitted an sBLA for Humira (adalimumab) for treatment of moderate-to-severe Crohn's disease, the company announced Sept. 7. Abbott is highlighting its anti-tumor necrosis factor monoclonal antibody's dosing advantage over Johnson & Johnson's anti-TNF MAb Remicade (infliximab); Humira is injected subcutaneously every other week for Crohn's, while Remicade requires infusion. UCB's Cimzia (certolizumab pegol), a fragment of an anti-TNF MAb, is also dosed subcutaneously and is likely to be approved for Crohn's before Humira: UCB submitted a BLA Feb. 28, 2006, and is predicting launch in the first half of 2007...

You may also be interested in...

UCB Modeling Itself After Genentech As Next-Generation Biopharma Firm

UCB’s imminent submission of Cimzia for rheumatoid arthritis slated for the end of the year is another step toward a stronger biotech presence for the company.

Independent Beauty Association Adds Global Supply-Chain Expertise; Cosmetics Appointments In Brief

The Honest Company’s new digital and strategy chief joins from where he led development of home security systems and contactless, in-garage delivery for more than 50m Amazon Key customers. More cosmetics people news, including new supply chain and sustainability leadership at the Independent Beauty Association.

A PDUFA First: Pre-Approval Inspection Notice Goal Will Be Created

Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts